THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 20 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $25,912,000 | -9.3% | 28,104,000 | -6.3% | 0.38% | +24.8% |
Q1 2022 | $28,562,000 | -0.8% | 30,000,000 | 0.0% | 0.31% | +8.1% |
Q4 2021 | $28,783,000 | +4.1% | 30,000,000 | 0.0% | 0.28% | +11.8% |
Q3 2021 | $27,640,000 | -3.2% | 30,000,000 | 0.0% | 0.25% | +9.5% |
Q2 2021 | $28,559,000 | -6.6% | 30,000,000 | 0.0% | 0.23% | -4.9% |
Q1 2021 | $30,580,000 | +7.7% | 30,000,000 | 0.0% | 0.24% | -6.9% |
Q4 2020 | $28,396,000 | +8.0% | 30,000,000 | 0.0% | 0.26% | -7.7% |
Q3 2020 | $26,281,000 | -9.9% | 30,000,000 | 0.0% | 0.28% | -22.0% |
Q2 2020 | $29,184,000 | +1.7% | 30,000,000 | 0.0% | 0.36% | -13.9% |
Q1 2020 | $28,688,000 | -7.8% | 30,000,000 | 0.0% | 0.42% | +23.0% |
Q4 2019 | $31,118,000 | +12.5% | 30,000,000 | 0.0% | 0.34% | +9.9% |
Q3 2019 | $27,656,000 | +7.5% | 30,000,000 | 0.0% | 0.31% | +34.3% |
Q2 2019 | $25,725,000 | -11.9% | 30,000,000 | 0.0% | 0.23% | -4.9% |
Q1 2019 | $29,213,000 | -5.3% | 30,000,000 | 0.0% | 0.24% | -8.6% |
Q4 2018 | $30,863,000 | -10.7% | 30,000,000 | 0.0% | 0.27% | +1.1% |
Q3 2018 | $34,575,000 | +15.4% | 30,000,000 | 0.0% | 0.26% | +1.1% |
Q2 2018 | $29,963,000 | -0.8% | 30,000,000 | 0.0% | 0.26% | -10.0% |
Q1 2018 | $30,206,000 | -8.6% | 30,000,000 | 0.0% | 0.29% | -11.0% |
Q4 2017 | $33,038,000 | -11.0% | 30,000,000 | 0.0% | 0.33% | -29.4% |
Q3 2017 | $37,125,000 | -8.1% | 30,000,000 | 0.0% | 0.46% | +0.4% |
Q2 2017 | $40,388,000 | +7.0% | 30,000,000 | 0.0% | 0.46% | +3.6% |
Q1 2017 | $37,763,000 | +10.9% | 30,000,000 | 0.0% | 0.44% | +0.2% |
Q4 2016 | $34,059,000 | – | 30,000,000 | – | 0.44% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|